[Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome].

Miwa Goto(Tokyo Metropolitan Kiyose Children's Hospital), Masataka Honda(Rikkyo University), Masahiro Ikeda(Shizuoka University), Yuko Hamasaki(Toho University), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Kenji Ishikura(Kitasato University)

PubMed

January 1, 2006

Cited by 7

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial

|The Lancet|2014|450

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

|Pediatric Nephrology|2022|278

Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease

|Clinical and Experimental Nephrology|2013|267

Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies

|Pediatric Nephrology|2021|149

A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment

|Kidney International|2014|135